Latest Advances in Anti-TNF Therapies in Inflammatory Bowel Disease (IBD)
Latest Advances in Anti-TNF Therapies in Inflammatory Bowel Disease (IBD) is organized by Prime Education, LLC.
Release Date: July 28, 2023
Expiration Date: July 27, 2024
Description:
Anti-TNF biologics have long been a mainstay in improving outcomes for patients with moderate to severe inflammatory bowel disease (IBD). More recently, innovations in new therapy formulations and a growing body of clinical evidence are equipping providers with tools to optimize treatment plans. Tune in to this insightful and interactive video presentation in which experts in the field will discuss the latest advances in anti-TNF therapies for IBD and strategies for optimizing therapy response. Test your knowledge through in-program polling and see how you stack up against your peers.
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3(opens in a new tab) of the Royal College's MOC Program.
Learning Objectives:
• Evaluate the latest efficacy and safety data from clinical trials and real-world studies of newer anti-TNF therapies in IBD
• Differentiate new and emerging anti-TNF therapy formulations for IBD
• Incorporate therapeutic drug monitoring strategies for IBD to optimize anti-TNF therapy
Agenda:
• Summary of Key Clinical Trial and Real-World Data Supporting the Safety and Efficacy of Infliximab and Adalimumab Therapies in Patients With Ulcerative Colitis and Crohn's Disease
• Differentiating Anti-TNF Therapy Formulations
• Optimizing Anti-TNF Therapy Response: Therapeutic Drug Monitoring
• Latest Evidence and Guideline Recommendations on Therapy Switching After Anti-TNF Failure